Indivior Appoints Joe Ciaffoni as Chief Executive Officer
Indivior PLC has made an important announcement, appointing Joe Ciaffoni as the new Chief Executive Officer. Currently serving as an Independent Non-Executive Director, Ciaffoni brings a wealth of knowledge and experience to the role, marking a significant leadership transition for the company.
Leadership Experience and Vision
With over 30 years in the pharmaceutical and biotech industries, Ciaffoni's background includes significant leadership roles, showcasing his capacity to manage both global and U.S. organizations effectively. His previous positions include serving as President and CEO of Collegium Pharmaceutical, alongside senior roles at Endo International, Biogen, and Shionogi Inc. This diverse experience positions him well to lead Indivior into its next chapter.
Transitioning Leadership Smoothly
Mark Crossley, the outgoing CEO, will assist in ensuring a smooth transition for Ciaffoni. His guidance is expected to maintain stability within the company during this crucial time, as he prepares to step down after a successful tenure that allowed Indivior to fortify its commitment to patients and expand critical access to addiction treatment.
Commitment to Patients
During Crossley's leadership, Indivior made substantial advancements in its mission to provide life-transforming treatments for substance use disorders. Under his direction, the company enhanced its focus on patient care and access to innovative therapies, solidifying its reputation as a leader in addiction treatment.
Looking Forward with Optimism
Ciaffoni expressed enthusiasm about his new role, emphasizing Indivior's vital mission in the addiction treatment space. He stated that it is both an honor and a responsibility to lead the company at such a pivotal moment. His commitment to stakeholders reflects his determination to harness Indivior's potential and drive forward its growth strategies.
Indivior's Commitment to Change Lives
As a global pharmaceutical company, Indivior is dedicated to transforming the landscape of addiction treatment. By developing medicines aimed at substance use disorders (SUD), the company envisions a world where all patients have access to evidence-based treatment for these chronic conditions. Their ongoing efforts aim to reshape public perception of SUD into a recognized and treated medical issue.
About Indivior
Headquartered in the United States, Indivior employs over 1,000 individuals and offers its products in more than 30 countries. The company continues to build upon its global portfolio, expanding its pipeline for opioid use disorder (OUD) treatments. Indivior remains committed to addressing the challenges posed by substance use and to providing effective treatment options.
Frequently Asked Questions
Who is Joe Ciaffoni?
Joe Ciaffoni is the newly appointed Chief Executive Officer of Indivior, transitioning from his role as Independent Non-Executive Director.
What experience does Joe Ciaffoni bring to Indivior?
Ciaffoni has over 30 years of experience in the pharmaceuticals and biotech sectors, holding various leadership roles in reputable organizations.
What were Mark Crossley's contributions to Indivior?
Mark Crossley, as CEO, enhanced Indivior's focus on patient care and expanded access to addiction treatments, significantly advancing the company's mission.
How does Indivior plan to address substance use disorders?
Indivior is dedicated to developing innovative medicines and expanding treatment options to help individuals struggling with substance use disorders.
Where is Indivior's headquarters located?
Indivior is headquartered in the United States, with a significant operational presence aimed at transforming the treatment landscape for addiction.
